Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 200 versus ISOVUE 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 200 versus ISOVUE 250.
ISOVUE-200 vs ISOVUE-250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby providing contrast enhancement in imaging studies. Its mechanism of action is physical rather than pharmacological, as it does not have inherent biological activity.
Intravenous administration of 1.0-2.0 mL/kg (200 mg iodine/mL) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 mL total. Maximum recommended dose: 2.0 mL/kg.
Intravenous administration of 50-150 mL (12-37 g iodine) for CT imaging; intra-arterial administration of 10-80 mL (2.5-20 g iodine) for angiography; dose depends on procedure and patient weight.
None Documented
None Documented
2 hours in normal renal function; prolongs up to 30 hours in severe renal impairment. Closely correlates with creatinine clearance.
Terminal elimination half-life: 1.5-2 hours (normal renal function); clinically, half-life prolonged in renal impairment
Renal: 100% unchanged as iohexol; glomerular filtration with no tubular reabsorption. No biliary/fecal elimination.
Primarily renal: 90-95% unchanged in urine within 24 hours; biliary/fecal: <5%
Category C
Category C
Contrast Media
Contrast Media